After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax (NVAX) ...

The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio. The expansion is fueled by increased ...

The purpose of the OWS grant was to enable Novavax to: ...complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 ...

Novavax has a bird flu vaccine in clinical trials in addition to a COVID-19/influenza combination vaccine in late-stage trials. The Louisiana Department of Health on Monday reported the first ...

Novavax faced setbacks late last year when the FDA placed its COVID-19 and influenza combination vaccine (CIC) on clinical hold due to a safety concern during trials. That hold was lifted within a ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

Maryland-based Novavax said it had enrolled the first participants in a phase 1/2 clinical trial of its coronavirus vaccine candidate. The vaccine, NVX-CoV2373, is a stable, prefusion protein ...